Comparison of methods of evaluating nephrotoxicity of cis-platinum
- PMID: 6987030
- DOI: 10.1038/clpt.1980.79
Comparison of methods of evaluating nephrotoxicity of cis-platinum
Abstract
The urinary excretion of leucine aminopeptidase (LAP), N-acetyl-beta-glucosaminidase (NAG), and beta 2-microglobulin was measured in 12 cancer patients receiving cis-platinum to evaluate the sensitivity of these indices for renal tubular damage. NAG and LAP excretion rose markedly in all patients, and beta 2-microglobulin rose in 11. Seven of the 9 patients who had received cis-platinum 6 wk before the study had prestudy dose elevations of one or more of these indices. We conclude that these urinary proteins are sensitive indicators of proximal renal tubular injury and may provide greater sensitivity for comparison of the nephrotoxic potential of future platinum analogs or for assessing the efficacy of regimens designed to protect the kidney from platinum nephrotoxicity than other measurements. The persistence of high excretion vales for these indices 6 wk after a dose demonstrates the persistent renal injury by cis-platinum.
Similar articles
-
[Comparison of methods for evaluating the nephrotoxicity of cisplatin].Gan To Kagaku Ryoho. 1988 Aug;15(8):2251-6. Gan To Kagaku Ryoho. 1988. PMID: 3044273 Japanese.
-
[Clinical investigation of cis-platinum nephrotoxicity in 244 cases of primary lung cancer].Nihon Jinzo Gakkai Shi. 1992 Jul;34(7):801-6. Nihon Jinzo Gakkai Shi. 1992. PMID: 1479719 Japanese.
-
Urinary excretion of beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase in advanced neuroblastoma patients receiving cis-diamminedichloroplatinum(II).Eur J Surg Oncol. 1988 Feb;14(1):17-20. Eur J Surg Oncol. 1988. PMID: 3278937
-
The diagnostic role of urinary N-acetyl-beta-D-glucosaminidase (NAG) activity in the detection of renal tubular impairment.Acta Medica (Hradec Kralove). 2005;48(2):75-80. Acta Medica (Hradec Kralove). 2005. PMID: 16259316 Review.
-
The role of NAG (N-acetyl-beta-D-glucosaminidase) in the diagnosis of kidney disease including the monitoring of nephrotoxicity.Clin Nephrol. 1992;38 Suppl 1:S14-9. Clin Nephrol. 1992. PMID: 1295704 Review.
Cited by
-
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.Cancer Chemother Pharmacol. 1982;9(3):140-7. doi: 10.1007/BF00257742. Cancer Chemother Pharmacol. 1982. PMID: 6761010
-
Evaluation of the nephrotoxicity of iproplatin (CHIP) in comparison to cisplatin by the measurement of urinary enzymes.Cancer Chemother Pharmacol. 1985;15(3):203-7. doi: 10.1007/BF00263886. Cancer Chemother Pharmacol. 1985. PMID: 4053265
-
Urinary beta 2-microglobulin: early indicator of high dose cisdiamminedichloroplatinum nephrotoxicity? Influence of furosemide.Cancer Chemother Pharmacol. 1986;18(3):276-9. doi: 10.1007/BF00273402. Cancer Chemother Pharmacol. 1986. PMID: 3542269
-
Phase I study of the cisplatin analogue 1,1-diamminomethylcyclohexane sulfatoplatinum (TNO-6) (NSC 311056).Cancer Chemother Pharmacol. 1985;15(2):97-100. doi: 10.1007/BF00257516. Cancer Chemother Pharmacol. 1985. PMID: 3893780
-
Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy.Exp Biol Med (Maywood). 2018 Feb;243(3):272-282. doi: 10.1177/1535370217745302. Epub 2017 Dec 12. Exp Biol Med (Maywood). 2018. PMID: 29231123 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials